

## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Cometriq Prior Authorization Policy

- Cometriq® (cabozantinib capsules – Exelixis)

**REVIEW DATE:** 06/15/2022

---

### OVERVIEW

Cometriq, a kinase inhibitor, is indicated for the treatment of patients with progressive, metastatic **medullary thyroid cancer**.<sup>1</sup>

### Guidelines

Cometriq is discussed in guidelines from the National Comprehensive Cancer Network (NCCN):

- **Non-Small Cell Lung Cancer:** NCCN guidelines (version 3.2022 – March 16, 2022) recommend the use of Cometriq for *RET* gene rearrangements (category 2A).<sup>2</sup>
- **Thyroid Carcinoma:** NCCN guidelines (version 2.2022 – May 5, 2022) list surgery as the main treatment option for medullary thyroid cancer.<sup>3</sup> Cometriq or Caprelsa® (vandetanib tablets) (category 1) are the preferred treatments for recurrent or persistent disease that is locoregional or metastatic. The guidelines also state that cabozantinib can be considered if patient has progression after Lenvima® (lenvatinib capsules) and/or Nexavar® (sorafenib tablets) for the treatment of locally recurrent, advanced, and/or metastatic disease that is not amendable to radioactive iodine therapy; this recommendation is for follicular, Hürthle cell, and papillary cancer subtypes (all category 2A).<sup>4</sup>

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Cometriq. All approvals are provided for the duration noted below.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Cometriq is recommended in those who meet one of the following criteria:

#### FDA-Approved Indication

1. **Thyroid Carcinoma, Medullary.** Approve for 1 year if the patient is  $\geq 18$  years of age.

#### Other Uses with Supportive Evidence

2. **Non-Small Cell Lung Cancer.** Approve for 1 year if the patient meets the following criteria (A and B):
  - A) Patient is  $\geq 18$  years of age; AND
  - B) Patient has *RET* gene rearrangements.
3. **Thyroid Carcinoma, Differentiated.** Approve for 1 year if the patient meets the following criteria (A, B, C and D):
  - A) Patient is  $\geq 12$  years of age; AND

06/15/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

- B) Patient has differentiated thyroid carcinoma; AND  
Note: Examples of differentiated thyroid carcinoma include papillary, follicular, and Hürthle cell thyroid carcinoma.
- C) The disease is refractory to radioactive iodine therapy; AND
- D) Patient has tried Lenvima (lenvatinib capsules) or Nexavar (sorafenib tablets).

#### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Cometriq is not recommended in the following situations:

1. **Metastatic Castration-Resistant Prostate Cancer (mCRPC).** Results from the COMET-1 Phase III pivotal study with cabozantinib 60 mg tablets in men with mCRPC are published.<sup>5</sup> Patients included in the study had disease progression after treatment with docetaxel as well as abiraterone acetate and/or Xtandi® (enzalutamide capsules). The study failed to meet its primary endpoint of demonstrating statistically significant increase in overall survival (OS) compared with prednisone. The median OS with cabozantinib was 11.0 months vs. 9.8 months with prednisone, which was not statistically significant. Based on these results, the second Phase III study, COMET-2 has been discontinued.<sup>6</sup>
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

#### REFERENCES

1. Cometriq® capsules [prescribing information]. San Francisco, CA: Exelixis; October 2020.
2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 3.2022 – March 16, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed June 13, 2022.
3. The NCCN Thyroid Carcinoma Clinical Practice Guidelines in Oncology (version 2.2022 – May 5, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed June 13, 2022.
4. The NCCN Drugs and Biologics Compendium. © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed June 13, 2022. Search term: cabozantinib.
5. Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. *J Clin Oncol*. 2016;34:3005-3013.
6. Exelixis. Study of cabozantinib (XL184) versus mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer (COMET-2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2017 March 13]. Available from: <http://www.clinicaltrials.gov/ct2/show/NCT01522443?term=NCT01522443&rank=1>. NLM identifier: NCT01522443.
7. Cabanillas ME, de Souza JA, Geyer S, et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter Phase II International Thyroid Oncology Group Trial. *J Clin Oncol*. 2017;35:3315-3321.

